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ABSTRACT: The interaction of Cardiac Troponin C (cTnC) and Cardiac Troponin I (cTnI) plays a critical
role in transmitting the Ca2+ signal to the other myoﬁlament proteins in the activation of cardiac muscle
contraction. As such, the cTnC-cTnI interface is a logical target for cardiotonic agents such as
levosimendan that can modulate the Ca2+ sensitivity of the myoﬁlaments. Evidence indicates that drug
candidates may exert their effects by targeting a site formed by binding of the switch region of cTnI to
the regulatory N domain of cTnC (cNTnC). In this study, we utilized two-dimensional 1H-15N HSQC
NMR spectroscopy to monitor the binding of levosimendan and its analogues, CMDP, AMDP, CI-930,
imazodan, and MPDP, to cNTnC·Ca2+ in complex with two versions of the switch region of cTnI
(cTnI147-163 and cTnI144-163). Levosimendan, CMDP, AMDP, and CI-930 were found to bind to both
cNTnC·Ca2+·cTnI147-163 and cNTnC·Ca2+·cTnI144-163 complexes. These compounds contain a methyl
group that is absent in MPDP or imazodan. Thus, the methyl group is one of the pharmacophores responsible
for the action of these pyridazinone drugs on cTnC. Furthermore, the results showed that the
cNTnC·Ca2+·cTnI144-163 complex presents a higher-afﬁnity binding site for these compounds than the
cNTnC·Ca2+·cTnI147-163 complex. This is consistent with our observation that the afﬁnity of cTnI144-163
for cNTnC·Ca2+ is ∼10-fold stronger than that of cTnI147-163, likely a result of electrostatic forces between
the N-terminal RRV extension in cTnI144-163 and the acidic residues in the C and D helices of cNTnC.
These results will help in the delineation of the mode of action of levosimendan on the important functional
unit of cardiac troponin that constitutes the regulatory domain of cTnC and the switch region of cTnI.
Regulation of cardiac muscle contraction by intracellular
Ca2+ is critical for normal heart function. This important task
is accomplished by the heterotrimeric troponin complex
anchored on the thin ﬁlament by its tropomyosin-binding
subunit cTnT.
1 The inhibitory subunit cTnI acts as a
molecular switch moving from actin to the Ca2+-binding
subunit cTnC as the intracellular Ca2+ concentration in-
creases. This switch is essential for transmitting the Ca2+
signal to the other myoﬁlament proteins, leading to tension-
producing cross bridges between actin and myosin and
ultimately activating cardiac muscle contraction (for recent
reviews, see refs 1 and 2).
Structural studies of troponin have helped in the elucida-
tion of the molecular mechanism that governs the switching
of cTnI to cTnC. cTnC is an “elongated” molecule with two
globular N and C domains connected by a ﬂexible linker in
solution (3). Apo cNTnC was shown to adopt a “closed”
conformation with most of its hydrophobic residues buried
(4). The energy barrier for “opening” is overcome by the
binding of Ca2+ and the switch region of cTnI (residues
∼147-163) (5, 6). In the NMR structure of the cNTnC·
Ca2+·cTnI147-163 complex (6) and the X-ray structure of the
cTnC·3Ca2+·cTnI31-210·cTnT183-288 complex (7), cTnI147-163
adopts an R-helical conformation and lies across the hydro-
phobic groove with contacts with key hydrophobic residues
in cNTnC. This interaction initiates the movement of the
adjoining inhibitory (cTnI128-147) and C-terminal (cTnI163-210)
regions of cTnI away from actin and releases the inhibition
of the actomyosin ATPase, leading to muscle contraction
(1). The cTnI34-71 region binds tightly to cCTnC in the
absence or presence of cytosolic Ca2+. In the structure of
cTnC·3Ca2+·cTnI31-210·cTnT183-288, the region of residues
34-71 of cTnI forms a long R-helix and makes extensive
contacts with the hydrophobic surface of cCTnC. Most
of the inhibitory region of cTnI is unobserved in
cTnC·3Ca2+·cTnI31-210·cTnT183-288, but a similar region of
sTnI is shown to have an extended conformation and interact
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the sTnC·4Ca2+·sTnI1-182·sTnT156-262 complex (8). Specif-
ically, the inhibitory region of sTnI was found to make
electrostatic contacts with the acidic residues on the central
DE-helix of sTnC, similar to those observed in the NMR
solution structure of cCTnC·2Ca2+·cTnI128-147 (9, 10).
The Ca2+-sensitive interaction between cNTnC and the
switch region of cTnI has been proposed to be an important
target for cardiotonic drugs (for reviews, see refs 1 and
11-15). These drugs are useful in the treatment of heart
disease associated with depressed cardiac contractility. They
act via a mechanism that modulates the Ca2+ sensitivity of
troponin without an overload of Ca2+ that would perturb the
regulation of other Ca2+-based signaling pathways in cardi-
omyocytes, leading to a series of undesirable side effects
such as arrhythmia and death. A good example is levosim-
endan, which has proven to be a well-tolerated and effective
treatment for patients with severe decompensated heart failure
(for reviews, see refs 13 and 14). Several cardiotonic agents
have been shown to target the binding site formed by cNTnC
and the switch region of cTnI. In the NMR structure of the
cNTnC·Ca2+·cTnI147-163·bepridil complex, bepridil and
cTnI147-163 bind concurrently to the hydrophobic pocket of
the protein (16). In the structure of the sTnC·4Ca2+·
sTnI1-182·sTnT156-262 complex, a polyoxyethylene detergent
molecule, anapoe, binds to sNTnC together with the switch
region of sTnI (sTnI115-131). This binding mode is likely
responsible for the increase in the contractile force of muscle
ﬁbers in the presence of anapoe (8). Further, we have shown
recently that a calmodulin antagonist, W7, binds to cNTnC
and the binding can occur in the presence of the switch region
of cTnI (17). Thus, these compounds, together with cT-
nI147-163, may exert their effects by altering the dynamic
equilibrium between closed and open cNTnC conformations,
enhancing the afﬁnity for cTnI and thereby modulating the
calcium sensitivity of troponin. Structures of cNTnC·
Ca2+·levosimendan or cNTnC·Ca2+·cTnI147-163·levo-
simendan are not yet available. NMR chemical shift mapping
has shown that levosimendan’s primary binding site is also
located in the N domain of cTnC in the presence of
cTnI (13, 18); however, the exact binding geometry has not
been established. To better delineate the binding site of
levosimendan in cNTnC, we investigated the binding of
levosimendan and its analogues (AMDP, CMDP, CI-930,
MPDP, and imazodan) (Figure 1) to cNTnC·Ca2+·
cTnI147-163 and cNTnC·Ca2+·cTnI144-163. cTnI144-163 is used
because the N-terminal RRV extension relative to cTnI147-163
is expected to be important for a network of interactions
responsible for the binding of drug molecules, on the basis
of structural analysis of the cNTnC·Ca2+·cTnI147-163·
bepridil and sTnC·4Ca2+·sTnI1-182·sTnT156-262 complexes.
We used two-dimensional (2D) 1H-15N HSQC NMR
spectral changes to monitor the formation of the
cNTnC·Ca2+·cTnI147-163 and cNTnC·Ca2+·cTnI144-163 com-
plexes and the titration of these complexes with drug
molecules. Our results revealed that only those compounds
containing the chiral methyl group induced chemical shift
changes, suggesting that this group constitutes a key phar-
macophore responsible for the binding of pyridazinone
derivatives to cNTnC. The ﬁndings also showed that the
pyridazinone compounds bound to cNTnC·Ca2+·cTnI144-163
with a higher afﬁnity than to cNTnC·Ca2+·cTnI147-163. This
correlates with our observation that the afﬁnity of cTnI144-163
for cNTnC·Ca2+ is ∼10-fold stronger than that of cTnI147-163,
likely a result of electrostatic forces between the N-terminal
RRV extension in cTnI144-163 and the acidic residues in the
C and D helices of cNTnC.
EXPERIMENTAL PROCEDURES
Sample Preparation. Recombinant human cNTnC (resi-
dues 1-89) with C35S and C84S mutations [denoted
cNTnC(C35S/C84S)] was used in this study. The engineering
of the expression vector and the expression of 15N-labeled
proteins in Escherichia coli were as described previously
(19). Two synthetic cTnI peptides, cTnI147-163 (acetyl-
RISADAMMQALLGARAK-amide) and cTnI144-163 (acetyl-
RRVRISADAMMQALLGARAK-amide), were obtained from
GL Biochem Ltd. (Shanghai, China). The purity was veriﬁed
by HPLC and the mass veriﬁed by electrospray mass
spectrometry. CMDP, AMDP, MPDP, and imazodan were
purchased from Sigma-Aldrich. AMDP and levosimendan
were purchased from Kinbester Co. Ltd. (Hong Kong). CI-
930 was obtained from Pﬁzer. Stock solutions of the
compounds in DMSO-d6 (Cambridge Isotopes Inc.) were
prepared, and the vials containing the solutions were wrapped
in aluminum foil due to sensitivity to light. All drug stock
solutions were made fresh for every titration to minimize
possible time-induced degradation. The concentrations were
determined gravimetrically. All NMR samples were 500 µL
in volume. The buffer conditions were 100 mM KCl, 10 mM
imidazole, and 0.17 mM DSS in a 90% H2O/10% D2O
mixture, and the pH was 6.7. DTT, NaN3, and protease
FIGURE 1: Chemical structures of (A) levosimendan, (B) CMDP,
(C) AMDP, (D) CI-930, (E) imazodan, and (F) MPDP.
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tions with the drug compounds. Hamilton syringes and
Gilson Pipetman P2 and P10 were used to deliver the drug
solutions for all titrations.
Compound Stereospeciﬁcity. The chiral lanthanide shift
reagent Eu-(hfc)3 (Sigma-Aldrich) was titrated into NMR
samples (all in CDCl3, Cambridge Isotopes Inc.) of levosi-
mendan, CMDP, AMDP, and CI-930 to determine whether
the methyl on the pyridazinone ring was stereospeciﬁc or if
the compounds were enantiomer mixtures (for a review, see
ref 20). All of the NMR spectra were obtained using a Varian
INOVA 500 MHz spectrometer at 30 °C. A 500 µL sample
volume was used for each compound, and TMS was used
to reference the spectra at 0 ppm. For each titration, 16
transients were acquired at each point. A 16.5 mM sample
of CI-930 was prepared, and a 0.27 M stock solution of Eu-
(hfc)3 was titrated into the solution at concentrations of 0.43,
0.86, 1.4, 1.94, 3.02, 4.1, 5.18, 6.26, 7.34, 8.42, 9.23, 12.47,
and 15.17 mM. A 17 mM CMDP sample was prepared and
titrated with a 0.322 M stock solution of Eu-(hfc)3 to yield
Eu-(hfc)3 concentrations of 1.28, 1.93, 2.6, 3.22, 4.5, 5.8,
11.6, and 17.6 mM. A 13.6 mM AMDP sample was prepared
and titrated with a 0.4 M stock solution of Eu-(hfc)3 to yield
ﬁnal concentrations of 1.73, 3.44, 5.14, 6.82, 8.5, and 10.2
mM. A 10 mM levosimendan sample was prepared, and
aliquots of Eu-(hfc)3 were added to the sample to yield 1.82,
3.6, 5.4, 7.18, and 8.65 mM Eu-(hfc)3. The one-dimensional
(1D) 1H NMR spectrum of each compound was assigned,
and the methyl was monitored throughout the titration with
chiral shift reagent Eu-(hfc)3 (Figure 2). The NMR signal
from the methyl of levosimendan did not undergo splitting
during the titration with Eu-(hfc)3, indicating that the drug
was of pure R stereospeciﬁcity (Figure 2A). Meanwhile, the
titration of Eu-(hfc)3 into the NMR samples of CMDP,
AMDP, and CI-930 revealed a splitting of the methyl
resonance, indicating that these compounds are racemic
mixtures of roughly equal R and S components (Figure 2B).
Titration of cNTnC(C35S/C84S)·Ca2+ with cTnI147-163 and
cNTnC(C35S/C84S)·Ca2+ with cTnI144-163. The titration of
[15N]cNTnC(WT)·Ca2+ with cTnI147-163 was conducted
previously (6), and the titration of [15N]cNTnC(C35S/
C84S)·Ca2+ (0.6 and 0.7 mM, respectively) with cTnI147-163
and cTnI144-163 was done in this work. Both cTnI147-163 and
cTnI144-163 are highly soluble in aqueous solution but tend
to form gels at high concentrations, likely due to aggregation.
Thus, no stock solution was prepared; instead, solid peptide
was added at every titration point. The concentrations of
[15N]cNTnC(C35S/C84S)·Ca2+ and the peptides were de-
termined by amino acid analysis at every titration point,
giving the peptide/protein ratios. The decrease in pH associ-
ated with peptide additions was offset by adjusting the pH
to 6.7 at every titration point. Both 1D 1H and 2D 1H-15N
HSQC NMR spectra were acquired and analyzed at every
titration point. Like in the titration of [15N]cNTnC(WT)·Ca2+
with cTnI147-163 (6), 3-3.5 equiv of cTnI147-163 is required
to saturate [15N]cNTnC(C35S/C84S)·Ca2+, whereas 1-1.1
equiv of cTnI144-163 is required to saturate [15N]cNTnC(C35S/
C84S)·Ca2+.
Titration of cNTnC(C35S/C84S)·Ca2+·cTnI147-163 and
cNTnC(C35S/C84S)·Ca2+·cTnI144-163 with LeVosimendan,
CMDP, AMDP, CI-930, Imazodan, and MPDP. The
[15N]cNTnC(C35S/C84S)·Ca2+·cTnI147-163 complex was
formed by dissolving 1 equiv of solid protein (0.8 mM) and
∼3.5 equiv of solid peptide (2.8 mM) in NMR buffer, and
the [15N]cNTnC(C35S/C84S)·Ca2+·cTnI144-163 complex was
formed by dissolving 1 equiv of solid protein (1.0 mM) and
∼1.1 equiv of solid peptide (1.1 mM) in NMR buffer. For
both complexes, 4 equiv of CaCl2 was added to saturate
cNTnC, the pH was adjusted to 6.7, and a slight amount of
precipitate was eliminated by ﬁltration. The ﬁnal NMR
sample volume was 500 µL. The protein and peptide
concentrations were determined gravimetrically and cali-
brated on the basis of amino acid analysis of each individual
component. Both 1D 1H and 2D 1H-15N HSQC NMR
spectra were acquired and analyzed at every titration point.
A stock solution of 97 mM levosimendan was used for
the titration of [15N]cNTnC(C35S/C84S)·Ca2+·cTnI147-163
in aliquots of 1.0, 1.0, 1.0, 1.0, 2.0, 4.0, 4.0, and 4.0 µL. A
stock solution of 95 mM levosimendan was used for the
titration of [15N]cNTnC(C35S/C84S)·Ca2+·cTnI144-163 in
volumes of 1.0, 2.0, 5.0, 5.0, 10.0, and 10.0 µL. The sample
was mixed thoroughly with each addition. In both cases,
levosimendan started to precipitate when the drug to protein
ratio reached ∼4/1. This precipitate is likely unbound
levosimendan, which is insoluble in aqueous solution. The
titrations were stopped shortly after the appearance of
precipitation. Addition of levosimendan slightly decreased
the pH, which was adjusted by adding 1 M NaOH to NMR
samples.
Aliquots of 1 µL of a 100 mM CMDP stock solution were
added to [15N]cNTnC(C35S/C84S)·Ca2+·cTnI147-163 and
[15N]cNTnC(C35S/C84S)·Ca2+·cTnI144-163. The titration
was stopped when white precipitate started to appear (after
the 8 µL addition). The change in pH from CMDP addition
was negligible.
FIGURE 2: Stacked spectra of the titration of levosimendan (A) and
CI-930 (B) with the shift reagent Eu-(hfc)3 as monitored by 1D 1H
NMR spectroscopy. From bottom to top, the [Eu-(hfc)3]/[CI-930]
ratios for each titration point are 0, 0.25, 0.34, 0.54, 0.72, and 0.84,
respectively. In the levosimendan titration series (A), no splitting
of the methyl resonance (*) is observed, while in the case of CI-
930 (B), splitting of the methyl resonance (*) is noticed, indicating
an R/S mixture of enantiomers with roughly equal concentrations.
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1.5, 5.0, 5.0, 8.0, and 8.0 µLo f[ 15N]cNTnC(C35S/
C84S)·Ca2+·cTnI147-163. AMDP is highly soluble in aqueous
solution, and no precipitate was observed even after the ﬁnal
aliquot. A stock of 100 mM AMDP was added in aliquots
of 0.5, 1.5, 5.0, 5.0, 8.0, and 10.0 µLt o[ 15N]cNTnC(C35S/
C84S)·Ca2+·cTnI144-163. Again, no precipitate was observed
during or after the titration. The change in pH from AMDP
addition was negligible.
Into a NMR tube containing [15N]cNTnC(C35S/C84S)·
Ca2+·cTnI147-163 were titrated aliquots of 1.0, 5.0, 5.0, 5.0,
5.0, and 5.0 µL of a 100 mM CI-930 stock solution. To the
[15N]cNTnC(C35S/C84S)·Ca2+·cTnI144-163 complex were
added aliquots of 0.25, 0.5, 2.5, 5.0, 5.0, 5.0, 5.0, and 5.0
µL of a 97 mM CI-930 stock solution. The change in pH
from CI-930 addition was negligible.
Imazodan precipitated after an addition of 1 µLo fa1 0 0
mM stock solution to the NMR sample of either [15N]-
cNTnC(C35S/C84S)·Ca2+·cTnI147-163 or [15N]cNTnC(C35S/
C84S)·Ca2+·cTnI144-163. This was also the case with MPDP.
Further additions resulted in more precipitation. No chemical
shift changes were observed for the imazodan and MPDP
titrations.
Pure DMSO-d6 was added to a NMR sample containing
[15N]cNTnC(C35S/C84S) to test if it would induce chemical
shift changes in [15N]cNTnC(C35S/C84S). No chemical shift
perturbations were observed in the 2D 1H-15N HSQC
spectrum upon addition of DMSO-d6 (data not shown). To
conﬁrm that levosimendan was not interacting with free
cTnI147-163 or cTnI144-163, levosimendan was titrated into
solutions containing either peptide. 1D 1H NMR revealed
no chemical shift change for cTnI147-163 or cTnI144-163 in
the presence of levosimendan, when compared to the spectra
acquired in the absence of the drug (data not shown).
NMR Spectroscopy. All of the NMR spectra were recorded
using a Varian INOVA 500 MHz spectrometer at 30 °C.
All 1D 1H and 2D 1H-15N HSQC spectra were acquired
using the water and gNhsqc.c pulse sequences, respectively
(BioPack, Varian Inc.). The CBCA(CO)NNH and HNCACB
NMR triple-resonance experiments (21) were conducted to
determine backbone assignments of the [13C,15N]cNTnC·
Ca2+·cTnI144-163 complex. Spectral processing was ac-
complished with VNMRJ (version 2.1B, Varian Inc.) and
NMRPipe (22) and referenced according to the IUPAC
conventions. Processed NMR spectra were analyzed using
NMRView (23), and the backbone assignment of
[13C,15N]cNTnC·Ca2+·cTnI144-163 complex was accom-
plished with the aid of Smartnotebook (24).
RESULTS
Throughout this study, 2D 1H-15N HSQC NMR spectra
were used to monitor the binding of unlabeled ligands (such
as the cTnI peptides, levosimendan, or its analogues) to 15N-
labeled cNTnC·Ca2+. In these titrations, the chemical shifts
of several assigned amide NH cross-peaks in the 2D 1H-15N
HSQC NMR spectrum of [15N]cNTnC·Ca2+ were perturbed
as a function of added ligand. In addition to the identiﬁcation
of ligands that associate with the 15N-labeled protein, the
changes in residue speciﬁc backbone shifts, which can be
quantiﬁed to derive ligand stoichiometry and afﬁnity, can
also be used to locate the ligand binding site on the protein.
This procedure is commonly known as chemical shift
mapping.
Interaction of cNTnC(C35S/C84S)·Ca2+ with cTnI147-163
and cTnI144-163. Previously, we titrated cTnI147-163 into
[15N]cNTnC(WT)·Ca2+ and demonstrated that the binding
of cTnI147-163 to cNTnC(WT)·Ca2+ caused large chemical
shift changes in the 2D 1H-15N HSQC NMR spectrum of
the protein, consistent with the structural transition in cNTnC
from a closed to an open state (6). The dissociation constant
(KD) of cTnI147-163 for cNTnC(WT)·Ca2+ was determined
to be 154 ( 10 µM. In this study, we found that the binding
of cTnI147-163 to cNTnC(C35S/C84S)·Ca2+ induced similar
backbone amide 1Ho r15N chemical shift changes, indicating
a similar closed to open transition. The stoichiometry of
binding of cTnI147-163 to cNTnC·Ca2+ was 1/1 in both the
WT and C35S/C84S isoforms. An expanded region of the
2D 1H-15N HSQC NMR spectra of cNTnC(C35S/C84S) free
and in the cNTnC(C35S/C84S)·Ca2+·cTnI147-163 complex
is depicted in Figure 3A, and peaks are labeled with residue
assignments. Many peaks within this region of the spectrum,
including V28, G34, V64, G68, and T71, moved in the
cTnI147-163 complex to characteristic chemical shifts corre-
sponding to an open conformation of cNTnC(C35S/C84S)
(shown by arrows connecting multiple and ﬁrst single
contours). When the longer peptide cTnI144-163 was titrated
into cNTnC(C35S/C84S)·Ca2+, the majority of the cross-
peaks in the 2D 1H-15N HSQC NMR spectrum of
cNTnC(C35S/C84S) shifted along nearly identical pathways
as in the titration of cTnI147-163 into cNTnC(C35S/
C84S)·Ca2+ but farther (shown by arrows connecting
multiple and second single contours). The 2D 1H-15N HSQC
NMR spectrum of cNTnC(C35S/C84S) in the cNTnC(C35S/
C84S)·Ca2+·cTnI144-163 complex has been assigned, and the
cross-peaks are labeled with residue assignments (Figure 3A).
The pattern of spectral changes is very similar for the two
complexes (Figure 3B) except for larger backbone amide
1Ho r15N chemical shift perturbations of cNTnC(C35S/C84S)
induced by cTnI144-163 in comparison with cTnI147-163. The
additional movements of the residues indicate that the binding
of cTnI144-163 generates a more stable open conformation
for cNTnC(C35S/C84S)·Ca2+ than cTnI147-163. The average
chemical shift changes of several residues that were perturbed
the most during titration are plotted as a function of
[cTnI144-163]total/[cNTnC(C35S/C84S)·Ca2+]total ratio (Figure
4), and the data were ﬁt to the following equation:
cNTnC(C35S/C84S)·Ca
2++cTnI144-163a
cNTnC(C35S/C84S)·Ca
2+·cTnI144-163
This yielded a macroscopic dissociation constant of 15 ( 5
µM, which is 10 times smaller than the dissociation constant
for cTnI147-163 binding to cNTnC(WT)·Ca2+ (6).
Interaction of cNTnC(C35S/C84S)·Ca2+·cTnI 147-163 and
cNTnC(C35S/C84S)·Ca2+·cTnI 144-163 with LeVosimendan,
CMDP, AMDP, and CI-930. The formation of the cNTnC-
(C35S/C84S)·Ca2+·cTnI147-163 and cNTnC(C35S/C84S)·
Ca2+·cTnI144-163 complexes were monitored by 2D 1H-15N
HSQC NMR spectroscopy (Figure 3A). The assigned
backbone amides of cNTnC(C35S/C84S) in the cNTnC(C35S/
C84S)·Ca2+·cTnI147-163 and cNTnC(C35S/C84S)·Ca2+·
cTnI144-163 complexes were then used to follow the titration
7488 Biochemistry, Vol. 47, No. 28, 2008 Robertson et al.of levosimendan, CMDP, AMDP, and CI-930 (Figure 1).
The initial (b) and end points (O) from the titrations of
cNTnC(C35S/C84S)·Ca2+·cTnI144-163 with (A) levosimen-
dan, (B) CMDP, (C) AMDP, and (D) CI-930 are shown in
Figure 5. In contrast to the dramatic chemical shift changes
induced by cTnI147-163 or cTnI144-163, those associated with
drug binding are much smaller. This suggests that unlike
the cTnI switch peptides, the drug compounds do not induce
a large structural opening of cNTnC(C35S/C84S) but rather
cause subtle perturbations on the interface between cNTnC-
(C35S/C84S) and the cTnI peptides. All four compounds
induced backbone amide chemical shift changes in a common
set of residues of both the cNTnC(C35S/C84S)·Ca2+·
cTnI147-163 and cNTnC(C35S/C84S)·Ca2+·cTnI144-163 com-
plexes. This suggests that the general location of binding is
similar for these pyridazinone derivatives. It is interesting
that although usually the same residues underwent perturba-
tions throughout the different classes of ligands, the chemical
shift changes were not always in the same direction. This
may be due to the different moieties present on the various
pyridazinone derivatives. To correlate the drug-induced
chemical shift changes of cNTnC(C35S/C84S) to confor-
mational changes in the protein, we plotted the changes for
backbone atoms against the protein sequence (Figure 6). The
magnitude of the changes was generally small but similar
to those reported in levosimendan binding to cTnC·3Ca2+
(25) and to cTnC·3Ca2+·cTnI32-79·cTnI128-180 (18). The
changes induced by levosimendan (Figure 6A) or CMDP
(Figure 6B) were relatively larger (e60 Hz) than those (e20
Hz) induced by AMDP (Figure 6C) and CI-930 (Figure 6D).
This indicates that the group attached to the aromatic ring
[mesoxalonitrile hydrazone in levosimendan, chloro in
CMDP, amino in AMDP, and imidazole in CI-930 (see
Figure 1)] inﬂuences the drug-protein-peptide interaction.
FIGURE 3: (A) Overlay of a well-dispersed region of the 2D 1H-15N
HSQC NMR spectra of cNTnC(C35S/C84S)·Ca2+ (multiple con-
tours), cNTnC(C35S/C84S)·Ca2+·cTnI147-163 (ﬁrst single contour),
and cNTnC(C35S/C84S)·Ca2+·cTnI144-163 (second single contour)
complexes. The arrows indicate the direction of chemical shift
change during titration of cTnI into cNTnC(C35S/C84S)·Ca2+.
Single contours represent the two cNTnC-cTnI complexes at the
end points of titrations. The end points were determined by the
cessation of chemical shift changes, which indicated a saturated
complex. (B) cTnI147-163-induced (white bars) and cTnI144-163-
induced (black bars) chemical shift changes of the backbone amides
of cNTnC(C35S/C84S). Chemical shifts are presented in hertz and
calculated as follows: ∆δ ) [(∆δ1Η)2 + (∆δ15Ν)2]1/2. Since hertz
is used instead of parts per million to calculate the total chemical
shift changes (∆δ), a correction factor of 1/5 in the 15N dimension
is not needed.
FIGURE 4: Titration of cNTnC(C35S/C84S)·Ca2+ with cTnI144-163.
The data are averaged over several residues with signiﬁcant
chemical shift changes observed during titration. The best-ﬁt curve
to the data is shown as a solid line. Conditions are described in
Experimental Procedures.
FIGURE 5: Titration of cNTnC(C35S/C84S)·Ca2+·cTnI144-163 [1.0
mM cNTnC(C35S/C84S) and 1.1 mM cTnI144-163] with (A)
levosimendan, (B) CMDP, (C) AMDP, and (D) CI-930 as moni-
tored by 2D 1H-15N HSQC NMR spectroscopy. The region of the
2D 1H-15N HSQC spectrum with well-dispersed resonances is
shown. Conditions are described in Experimental Procedures.
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pyridazinone ring which may be in direct contact with the
protein and involved in anchoring the drug molecules to
cNTnC(C35S/C84S)·Ca2+·cTnI144-163. This is supported by
the observation that cNTnC(C35S/C84S)·Ca2+·cTnI147-163
and cNTnC(C35S/C84S)·Ca2+·cTnI144-163 do not interact
with imazodan or MPDP, as represented by the lack of
chemical shift perturbations.
To elucidate the binding site of levosimendan on cNTnC-
(C35S/C84S)·Ca2+·cTnI144-163, chemical shift mapping is
shown in Figure 7. The solution structure of cNTnC·Ca2+·
cTnI147-163 [Protein Data Bank (PDB) entry 1MXL] was used
to map the ﬁnal chemical shift changes induced by the
titration of levosimendan into cNTnC(C35S/C84S)·Ca2+·
cTnI144-163. The chemical shift perturbations are mapped on
the structure by magnitude such that the chemical shift
changes for residues colored pink were greater than the mean
(µ), the chemical shift changes for residues colored dark
salmon were one standard deviation above the mean chemical
shift change (µ + σ), and the chemical shifts for residues
colored red were two standard deviations above the mean
(µ + 2σ) (see Figure 6A). Chemical shift mapping of CMDP
on the structure of cNTnC·Ca2+·cTnI147-163 (PDB entry
1MXL) resulted in a surface nearly identical to that of
levosimendan.
Binding Afﬁnity Determination. The calculation of the
afﬁnities of the different drugs is illustrated in Figure 8. Data
analysis of the titration of CI-930 into cNTnC(C35S/
C84S)·Ca2+·cTnI147-163 and cNTnC(C35S/C84S)·Ca2+·
cTnI144-163 is shown as an example. An expanded region of
2D 1H-15N HSQC NMR spectral changes induced by CI-
930 is shown in panels A and C of Figure 8. Plots of
chemical shift changes of L48 as a function of [CI-930]total/
[cNTnC(C35S/C84S)·Ca2+·cTnI147-163]total and [CI-930]total/
[cNTnC(C35S/C84S)·Ca2+·cTnI144-163]total are shown in
panels B and D of Figure 8, respectively. In both cases, no
plateau could be reached in the titration even at high protein/
drug ratios, indicating weak binding. A global ﬁtting ap-
proach (www.bionmr.ualberta.ca/bds/software/xcrvﬁt) was
used, in which the data for residues perturbed during titration
were ﬁt to the following equation:
protein+drugaprotein·drug
yielding a KD of 11 mM for CI-930 binding to cNTnC(C35S/
C84S)·Ca2+·cTnI147-163 and 2.65 mM for CI-930 binding
cNTnC(C35S/C84S)·Ca2+·cTnI144-163. For levosimendan,
the KD values are 8 and 0.7 mM, respectively, and for
AMDP, those are 6.5 and 1.5 mM, respectively. We were
not able to obtain the dissociation constants for CMDP due
to the precipitation of the ligand prior to reaching a 1/1
stoichiometry. The results for levosimendan, AMDP, and CI-
930 demonstrate that cNTnC(C35S/C84S)·Ca2+·cTnI144-163
presents a more complete binding site for the drug molecules
than cNTnC(C35S/C84S)·Ca2+·cTnI147-163.
FIGURE 6: (A) Levosimendan, (B) CMDP, (C) AMDP, and (D) CI-930-induced chemical shift changes of the backbone amides of
cNTnC(C35S/C84S) in the cNTnC(C35S/C84S)·Ca2+·cTnI144-163 complex [1.0 mM cNTnC(C35S/C84S) and 1.1 mM cTnI144-163]. Chemical
shift changes are presented in hertz and calculated as follows: ∆δ ) [(∆δ1Η)2 + (∆δ15Ν)2]1/2. Since hertz is used instead of parts per
million to calculate the total chemical shift changes (∆δ), a correction factor of 1/5 in the 15N dimension is not needed. Horizontal lines in
the levosimendan and CMDP bar diagrams (A and B) show total chemical shift perturbations larger than the mean (µ), the mean plus one
standard deviation (µ + σ), and the mean plus two standard deviations (µ + 2σ). These values were used for chemical shift mapping.
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The goal of this study was to deﬁne the binding site of
levosimendan and several structural analogues (Figure 1) in
the regulatory domain of cTnC in complex with the switch
region of cTnI, as well as to gain insight into the particular
pharmacophores responsible for the binding of the ligands
to the cNTnC-cTnI complex. An attractive aspect of this
complex is that the interaction between cNTnC and the
switch region of cTnI is Ca2+-sensitive and the binding of
Ca2+ and the cTnI switch are coupled to the opening of the
cNTnC hydrophobic pocket, revealing an important target
for cardiotonic drugs. We utilized 2D 1H-15N HSQC NMR
spectroscopy to monitor the formation of two cTnC-cTnI
complexes, cNTnC(C35S/C84S)·Ca2+·cTnI147-163 and
cNTnC(C35S/C84S)·Ca2+·cTnI144-163, and the titration of
six drug compounds to those complexes. Since 2D 1H-15N
HSQC NMR spectroscopy can report information pertaining
to individual atoms throughout the protein sequence, we were
able to detect the subtle chemical shift changes of drug
binding on the backbone amides of cNTnC(C35S/C84S) in
the presence of cTnI147-163 or cTnI144-163 peptides. These
measurements allowed the identiﬁcation of a combination
of speciﬁc amino acids in cNTnC and cTnI that form a
binding pocket to accommodate the chiral methyl group on
the pyridazinone ring of levosimendan and its analogues.
The structure of the cNTnC-cTnI complex has been
characterized in several studies. We have shown that the
binding of cTnI147-163 induces a structural opening in
cNTnC·Ca2+ (6). In the structure of cNTnC·Ca2+·
cTnI147-163, the bound cTnI147-163 peptide adopts an R-helical
conformation spanning residues 4-12 in the 17-residue
peptide. With the N-terminus of the peptide interacting with
the center of the hydrophobic pocket, the R-helical region
interacts with the AB helical interface and stabilizes the
opening conformation of cNTnC·Ca2+. The corresponding
sTnI115-131 peptide adopts a similar structure and a similar
mode of interaction with sNTnC as observed in the structure
of sNTnC(rhodamine)·2Ca2+·sTnI115-131 (26). The backbone
atoms of the cNTnC·Ca2+·cTnI147-163 structure super-
impose to 1.5 Å with the corresponding regions in the X-ray
structure of the cardiac troponin complex cTnC·3Ca2+·
cTnI31-210·cTnT183-288. Addition of bepridil to cNTnC·Ca2+·
cTnI147-163 resulted in the cNTnC·Ca2+·cTnI147-163·
bepridil ternary complex, with the binding site for cTnI147-163
primarily located on the AB interhelical interface and the
binding site for bepridil in the center of the hydrophobic
pocket (16). A similar binding scenario was observed in the
X-ray structure of the sTnC·4Ca2+·sTnI1-182·sTnT156-262
complex (8), in which a detergent molecule, anapoe, was
found to bind together with the switch region of sTnI to
sNTnC·2Ca2+ (8). In the structure of sTnC·4Ca2+·
sTnI1-182·sTnT156-262, the three-residue extension (R112,
R113, and V114) in the N-terminus of sTnI115-131 is involved
in electrostatic contacts with a number of acidic residues in
both the C and D helices of sNTnC (Figure 9), which may
enhance the stability of the open conformation of
sNTnC·2Ca2+. Although R144, R145, and V146 are not
visualized in the cNTnC·Ca2+·cTnI147-163 and cTnC·
3Ca2+·cTnI31-210·cTnT183-288 structures, these residues were
expected to be located in the proximity of the corresponding
acidic residues, D87 and D88, in the D helix of cNTnC. This
is based on the observation that the binding of the switch
region of TnI to the N domain of TnC is the same in all the
structures mentioned above. Thus, it is reasonable to suggest
that cNTnC·Ca2+·cTnI144-163 would present a more stable
complex with a higher-afﬁnity binding site for drug com-
pounds than cNTnC·Ca2+·cTnI147-163. This is in line with
the observation in this work.
An earlier study has shown that the binding site of
levosimendan is in the N domain of Ca2+-saturated cTnC
(27), although this was challenged by a different analysis
showing that levosimendan did not bind to cTnC or a
cTnC-cTnI complex (28). The later report showed that the
inability to observe the levosimendan binding to cTnC was
in part due to sample degradation and the use of a
recombinant cTnC with C35 and C84 mutated to serines (25).
It suggested that C84 is necessary for the interaction of
levosimendan and cTnC. Furthermore, this report showed
that levosimendan is capable of binding to both domains of
FIGURE 7: Surface representations of cNTnC·Ca2+·cTnI147-163
(PDB entry 1MXL). The cNTnC·Ca2+·cTnI147-163 complex is
colored yellow with the helices of troponin C labeled. cNTnC·Ca2+
is depicted as a surface representation, whereas cTnI147-163 is shown
in ribbon format. Chemical shift perturbations induced by levosi-
mendan (A) and CMDP (B) binding to cNTnC·Ca2+·cTnI144-163
are colored on the basis of the magnitude of the chemical shift.
Chemical shifts greater than the mean plus two standard deviations
(µ + 2σ) are colored red, greater than the mean plus one standard
deviation (µ + σ) dark salmon, and greater than the mean (µ)
salmon.
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to demonstrate that levosimendan bound to only the N
domain of cTnC in the presence of cTnI32-79 and cTnI128-180.
Levosimendan-induced amide chemical shift changes were
detected throughout the N domain of cTnC in the presence
of the cTnI peptides. A number of N domain resonances
either were broadened beyond detection or exhibited multiple
chemical shifts. A large number of both polar and nonpolar
residues that exhibited chemical shift changes upon levosi-
mendan binding precluded identiﬁcation of the levosimen-
dan-binding site on cNTnC. Sorsa et al. (18) attributed the
numerous N domain chemical shift changes to levosimendan
altering either the dynamic equilibrium or the rate of
exchange between open and closed N domain conformations
by partially stabilizing defunct Ca2+ site I in cNTnC·Ca2+.
The exact binding location of levosimendan on cTnC
remained unclear, although all the studies cited above
suggested that its binding site is in the proximity of M81,
M85, and F77 (residues on the D helix) within the hydro-
phobic pocket of cNTnC. Our data are in agreement with
these studies and show that levosimendan targets the
hydrophobic pocket of cNTnC. The chemical shift mapping
depicted in Figure 7 indicates that all backbone amide
resonances perturbed modestly (colored salmon) belong to
the residues in the hydrophobic pocket, whereas the residues
that are more signiﬁcantly perturbed (colored dark salmon
and red) belong to the N and A helices, away from the
proposed binding surface. We suggest that the larger chemi-
cal shift perturbations of residues, such as Y5 and I4 on the
N helix and A23 and F24 on the A helix, may be due to a
slight conformational change of cNTnC·Ca2+·cTnI144-163
upon binding levosimendan, whereas the residues with
smaller chemical shift changes identify the binding site of
levosimendan in cNTnC·Ca2+·cTnI144-163 more accurately.
The conformational change may be similar to that observed
in the binding of bepridil to cNTnC·Ca2+·cTnI147-163,
where in addition to the opening of cNTnC, there is a slight
shift in the position of cTnI147-163 (15). Our results demon-
strated that the conserved positively charged N-terminal
extension (RRV) in cTnI144-163 is important for enhancing
the afﬁnity of levosimendan for cNTnC·Ca2+. Thus, the
network of electrostatic interactions between R144 and R145
of cTnI and D87 and D88 of cNTnC and the hydrophobic
interactions between the helical region of cTnI147-163 and the
hydrophobic surface of cNTnC·Ca2+ create the levosimendan
binding site with enhanced afﬁnity, with a net result of the
stabilization of the hydrophobic pocket and the open
conformation of cNTnC·Ca2+. We propose that the position
FIGURE 8: Selected region of 2D 1H-15N HSQC NMR spectra demonstrating the progressive shifts of L48 during the CI-930 titration to
cNTnC(C35S/C84S)·Ca2+·cTnI147-163 (A) and to cNTnC(C35S/C84S)·Ca2+·cTnI144-163 (C). Chemical shift changes of L48 were plotted
as a function of [CI-930]total/[cNTnC(C35S/C84S)·Ca2+·cTnI147-163]total (B) and [CI-930]total/[cNTnC(C35S/C84S)·Ca2+·cTnI144-163]total
(D). The best-ﬁt curves to the data are shown as solid lines.
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to that of anapoe in the skeletal troponin complex (Figure
9) on the basis of the results of chemical shift mapping
(Figures 7). The A-Cys version of cNTnC was used in this
study, and our results show that a cTnC-cTnI complex
provides a favorable binding site for levosimendan in the
absence of C84. The study (25) reporting that C84 is critical
for the interaction of levosimendan and cNTnC suggested
that the C84S mutation may slightly alter the conformation
of the D helix of cNTnC to render the levosimendan binding
site unavailable. Our results show that electrostatic interac-
tions between R144 and R145 of cTnI and D87 and D88 of
cNTnC help to stabilize the D helix and thereby the binding
site for levosimendan. Covalent modiﬁcation of C84 by
levosimendan provides a plausible mechanism to account for
the levosimendan-dependent effects (e.g., splitting of NMR
peaks) observed by Sorsa et al. (25). This potential covalent
interaction between C84 and levosimendan may not be
required for its binding to the troponin complex but may
subsequently occur in vivo (29).
To understand the effect of the pharmacophores of
levosimendan on binding to cNTnC, we investigated the
binding of several levosimendan analogues (Figure 1) to
cNTnC·Ca2+·cTnI147-163 and cNTnC·Ca2+·cTnI144-163.
Among the derivatives, only those containing the chiral
methyl group induced chemical shift changes, suggesting that
this group constitutes a key pharmacophore responsible for
the binding of pyridazinone derivatives to cNTnC(C35S/
C84S)·Ca2+. This is probably because this methyl group
contributes to the hydrophobic packing in a stereospeciﬁc
manner. This type of interaction is demonstrated in the
binding of EMD 57033 to the C domain of cTnC (30, 31).
In the structure of cCTnC·2Ca2+·EMD 57033, the drug
molecule is oriented such that the chiral methyl group of
EMD 57033 ﬁts deep in the hydrophobic pocket and makes
several key contacts with the protein. This stereospecifc
interaction explains why the (-)-enantiomer of EMD 57033
(EMD 57439) is inactive. Studies on the action of stereoi-
somers of simendan (levosimendan and its + enantiomer,
dextrosimendan) on cTnC have presented evidence that the
Ca2+ sensitizing effect of levosimendan is in part due to a
stereoselective binding to the N domain of cTnC (32).
Another cardiotonic drug with structural characteristics
similar to those of levosimendan, pimobendan, binds troponin
and increases calcium sensitivity in a stereospeciﬁc manner
as well (33, 34). The three levosimendan analogues that
associated with cNTnC·Ca2+·cTnI147-163 and cNTnC·Ca2+·
cTnI144-163, CMDP, AMDP, and CI-930 were shown in this
work to be R/S mixtures (Figure 2); therefore, we cannot
unambiguously conclude that binding to the complex is
selective for one enantiomer over the other. However, it is
possible that the afﬁnity of one of the enantiomers of the
pyridazinone compounds with cNTnC·Ca2+·cTnI144-163 is
higher than that of the other.
In addition to the chiral methyl group on the pyridazinone
ring, a group attached to the benzene ring may also be
important in the binding. In levosimendan, this is a bulky
group comprised of the mesoxalonitrile hydrazone moiety.
Structure-activity analysis of levosimendan analogues has
shown that this group is involved in hydrogen bonding with
cTnC, indicating that both hydrogen bonds and van der
Waals contacts are formed upon the binding of active
levosimendan analogues to cTnC (35). Our data showed that
levosimendan and CMDP induced larger chemical shift
changes than AMDP and CI-930 (Figure 6). This demon-
strates that the mesoxalonitrile hydrozone group in levosi-
mendan and the chloro group in CMDP help to form stronger
interactions with the binding site compared to the amino
group in AMDP or the imidazole group in CI-930. Chemical
shift mapping (Figure 7) identiﬁes a similar binding site
between levosimendan and CMDP located in the hydropho-
bic pocket of cNTnC·Ca2+·cTnI144-163. The large chemical
FIGURE 9: (A) Ribbon diagram of sNTnC·2Ca2+·sTnI112-131·anapoe
(PDB entry 1YTZ). sNTnC is colored light gray, sTnI112-132 dark
gray, anapoe yellow, and calcium black. Six negatively charged
residues of sNTnC (s) and cNTnC (c) are labeled. (B) Electrostatic
surface map of sNTnC, with the potential contours shown at +20
kBT/e (blue) and -20 kBT/e (red). sTnI112-131 is colored dark gray
and shown as a ribbon diagram, with the three extra residues from
the inhibitory region of sTnI, R112, R113, and V114, depicted as
sticks. (C) Electrostatic surface map of sTnI112-131, with the potential
contours shown at +20 kBT/e (blue) and -20 kBT/e (red). Positively
charged R112 and R113 are labeled on the electrostatic surface
map. Surface maps were generated with ABPS (41).
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cNTnC induced by CMDP suggest a structural opening of
cNTnC·cTnI144-163. The larger chemical shift changes of
residues along the D helix of cNTnC from CMDP binding
when compared with those of levosimendan may be due to
the proximity of these residues to the electronegative chloro
group of CMDP, or a slightly different binding mode
between the ligands. The perturbed chemical shifts along the
B helix induced by levosimendan may result from a larger
displacement of cTnI144-163 by the voluminous mesoxaloni-
trile hydrazone moiety when compared with CMDP. As-
suming the binding mode of levosimendan and its analogues
is similar to that of anapoe (Figure 9), the orientation of the
pyridazinone molecules would be antiparallel to cTnI144-163;
i.e., the chiral methyl group on the pyridazinone ring ﬁts
deep in the hydrophobic cavity, whereas the group attached
to the aromatic ring makes contacts with the residues in the
N-terminus of cTnI144-163 and the D helix of cNTnC.
Interestingly, EMD 57033 also binds to the hydrophobic
pocket of cCTnC in a similar manner, with the chiral methyl
group deep inside the protein core.
The afﬁnities determined for the binding of levosimendan
(KD ∼ 0.7 mM), AMDP (KD ∼ 1.5 mM), and CI-930 (KD ∼
2.6 mM) to cNTnC·Ca2+·cTnI144-163 are comparable to those
from the previous studies on levosimendan binding to
cTnC·3Ca2+·cTnI32-79·cTnI128-180 (KD g 0.2 mM) (18), W7
binding to cTnC·3Ca2+·cTnI34-71·cTnI128-163 (KD ∼ 0.5
mM) (17), and anapoe binding to sTnC·4Ca2+·sTnI1-182·
sTnT156-262 (KD ∼ 0.64 mM) (8). This might support the
notion that the binding of cardiotonic drugs to the regulatory
unit of cardiac troponin occurs in a similar mode. These KD
values are in the high micromolar range, which is generally
considered weak for protein-drug interactions. Levosimen-
dan is known to exert multiple effects on perfused hearts at
concentrations as low as 0.3 µM; the effect of levosimendan
on skinned muscle ﬁbers was half-maximal by 0.3 µM and
maximal by 10 µM( 36), and similar levels of levosimendan
modulated contractility in cardiomyocytes (37). Several
factors could contribute to this phenomenon. Micellization
of drug molecules in aqueous solutions has been shown to
cause low apparent afﬁnities (38, 39). It is possible that cTnC
in the highly organized and cooperative myoﬁlaments may
have a higher afﬁnity for levosimendan than it does when
cTnC is isolated in solution. On the other hand, the weak
levosimendan-cTnC interaction may allow the drug to
gently modulate cardiac contractility in a rhythmic fashion
so that cardiac relaxation is not compromised. This is in
accordance with a study reporting a KD of >2 mM for the
interaction of pineal hormone melatonin and calmodulin. The
low afﬁnity has been used to explain many in vitro effects
and pharmacological dosages of melatonin (40). The small
chemical shift changes observed in this study suggest that
these drug molecules do not induce large conformational
changes in cNTnC·Ca2+·cTnI144-163. This feature is poten-
tially useful for the rapid mapping of the drug molecules to
the already determined structure of cNTnC·Ca2+·cTnI147-163
via measurement of the intermolecular NOE restraints
between cNTnC·Ca2+·cTnI147-163 and the drug molecules,
a project currently in progress in our laboratory.
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